Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review

Area of Science:

• Oncology
• Medicinal Chemistry

Background:

• Cancer remains a leading cause of death globally, necessitating novel therapeutic strategies.
• Doxorubicin is a widely used chemotherapy drug, but faces challenges like drug resistance and toxicity.
• Current treatment limitations highlight the need for innovative approaches to cancer therapy.

Purpose of the Study:

• To review advancements in hybrid compounds combining doxorubicin scaffolds with other chemotherapeutic agents.
• To explore the potential of these hybrid molecules as effective anticancer drugs.
• To provide an update on the development of novel doxorubicin-based hybrid therapeutics.

Main Methods:

• Literature review of scientific publications on doxorubicin hybrid compounds.
• Analysis of studies reporting on the synthesis and efficacy of these hybrid molecules.
• Evaluation of data on chemotherapeutic effects and potential side effects.

Main Results:

• Hybrid compounds integrating doxorubicin scaffolds demonstrate potent chemotherapeutic effects.
• Combination strategies can potentially mitigate resistance and reduce toxicity associated with doxorubicin monotherapy.
• Emerging hybrid molecules show promise for enhanced anticancer activity.

Conclusions:

• Hybridization of doxorubicin with other chemotherapeutic agents is a promising strategy for developing next-generation cancer treatments.
• Further research into doxorubicin-based hybrids could lead to more effective and safer cancer therapies.
• These novel compounds represent a significant advancement in the fight against cancer.